With such a performance, Mad Square earned a rocking 7.90 crore* net at the Indian box office on day 1, registering the 5th biggest start for Tollywood in 2025. Released in 2023, Mad earned 1.20 ...

To find the best automatic litter boxes worth investing in (and yes, they are an investment), I enlisted my three favorite felines to put seven top contenders to the test. In our collective ...

So skip the dressing room: The best clothing subscription boxes for women deliver a curated assortment of clothing and accessories right to your door, minus shipping fees or complicated commitment ...

Paris: Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific ...

MAD Square Worldwide Break-even Target: Written and directed by Kalyan Shankar, who made his debut with Mad (2023), MAD Square is the sequel to the film which stars Narne Nithiin and Sangeeth ...

Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to $1.9B. The French pharmaceutical company will acquire DR-0201, a CD20 ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.

PARIS, France I March 20, 2025 I Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bio’s autoimmune disease treatment, DR-0201, reinforcing its expansion in the biopharmaceutical sector. The French healthcare giant ...

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion. The French pharmaceutical company on Thursday said it would ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, ...